IL-33, sST2 and CRP levels in panic disorder
Investigation of IL-33, sST2, and C-Reactive Protein in Panic Disorder: A Cross-Sectional Case-Control Study
We are testing whether blood levels of IL-33, sST2, and CRP differ between adults with panic disorder who have never taken psychiatric medication and healthy people.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Elazığ Mental Health and Diseases Hospital Government |
| Locations | 1 site (Elâzığ, Elâzığ) |
| Trial ID | NCT07444879 on ClinicalTrials.gov |
What this trial studies
This is a cross-sectional, case-control study enrolling drug-naïve adults with DSM-5 panic disorder and matched healthy controls, planned at about 40 participants per group. Participants complete demographic forms and the Panic Disorder Severity Scale, then give a fasting morning blood sample. Serum IL-33, sST2, and CRP will be measured by commercial ELISA kits and compared between groups. Statistical analyses will include group comparisons, correlations, regression, and ROC analysis to explore marker differences and diagnostic performance.
Who should consider this trial
Good fit: Adults 18–65 with a DSM-5 diagnosis of panic disorder who are drug-naïve, free of major medical or autoimmune disease, and willing to fast and provide a blood sample are ideal candidates.
Not a fit: People already taking psychiatric medications or with active infections, autoimmune disease, pregnancy, major medical illnesses, or other active psychiatric disorders are unlikely to benefit from this specific comparison.
Why it matters
Potential benefit: If successful, the study could identify inflammatory blood markers that improve understanding of biological processes in panic disorder and help guide future diagnostic or treatment research.
How similar studies have performed: Previous work has reported higher CRP in panic disorder, but IL-33 and its receptor sST2 have not been previously studied in panic disorder, making this a novel biomarker evaluation.
Eligibility criteria
Show full inclusion / exclusion criteria
1. For Panic Disorder (PD) Group:
\*Inclusion Criteria:
* Being between 18-65 years of age
* Having a diagnosis of panic disorder (PD) according to DSM-5-TR and having presented to the hospital with panic attack symptoms of the disorder
* Not having previously used any medication for psychiatric purposes (drug-naive)
* Not having any additional active psychiatric disorders besides PD at the current presentation
* Absence of hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer
* Not having taken any medication or supplements in the last month
* Completing sociodemographic and scale data fully
* Volunteering to participate in the study
For PD Group:
\*Exclusion Criteria:
• Being outside the 18-65 age range
• Not meeting the diagnostic criteria for PD according to DSM-5-TR or being in good health
• Having a history of psychiatric medication use
• Having an additional psychiatric disorder besides PD at the current application
• Presence of hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, cancer
• Patients with a body mass index (BMI) \<18.5 kg/m² and \>29.9 kg/m²
* Taking any medication or supplement in the last month
* Incomplete completion of sociodemographic and scale data
* Not volunteering to participate in the study
2. For Healthy Control Group:
* Inclusion Criteria:
* Being between 18-65 years of age
* Not having any active psychiatric disorder
* Not having previously used any medication for psychiatric purposes (drug-naive)
* Not having hypertension, diabetes mellitus, kidney failure, liver failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer
* Not having taken any medication or supplement in the last month
* Completing sociodemographic and scale data fully
* Volunteering to participate in the study
For Healthy Control Group:
\*Exclusion Criteria:
* Being outside the 18-65 age range
* Having any active psychiatric disorder
* Having a history of using psychiatric medication
* Having hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer
* Patients with a body mass index (BMI) \< 18.5 kg/m² and \> 29.9 kg/m²
* Taking any medication or supplement in the last month
* Incomplete completion of sociodemographic and scale data
* Not volunteering to participate in the study
Where this trial is running
Elâzığ, Elâzığ
- Elazığ Mental Health and Diseases Hospital Psychiatry Clinic — Elâzığ, Elâzığ, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Mehmet Hamdi ÖRÜM, MD, Ass. Prof., Psychiatrist
- Email: mhorum@hotmail.com
- Phone: +905382207558
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.